JPMorgan Chase & Co. started coverage on shares of United Therapeutics (NASDAQ:UTHR) in a research note issued to investors on Monday morning, The Fly reports. The brokerage issued an overweight rating on the biotechnology company’s stock.
Other research analysts also recently issued reports about the stock. Wedbush reiterated a buy rating and set a $244.00 price target (up from $243.00) on shares of United Therapeutics in a report on Wednesday, July 29th. Oppenheimer lifted their price target on United Therapeutics from $155.00 to $165.00 and gave the company an outperform rating in a research note on Thursday, July 30th. ValuEngine upgraded shares of United Therapeutics from a strong sell rating to a sell rating in a report on Monday, August 3rd. Cowen reissued a buy rating and set a $145.00 target price on shares of United Therapeutics in a report on Friday, June 12th. Finally, TheStreet lowered shares of United Therapeutics from a b rating to a c rating in a report on Wednesday, July 29th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $141.67.
UTHR stock opened at $106.08 on Monday. The company has a quick ratio of 7.08, a current ratio of 7.43 and a debt-to-equity ratio of 0.26. United Therapeutics has a 12 month low of $75.58 and a 12 month high of $127.79. The firm has a market cap of $4.71 billion, a P/E ratio of 10.89 and a beta of 0.74. The company’s 50-day moving average price is $108.29 and its two-hundred day moving average price is $108.71.
United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $2.41 EPS for the quarter, meeting the consensus estimate of $2.41. United Therapeutics had a net margin of 30.04% and a return on equity of 14.90%. The firm had revenue of $362.00 million for the quarter, compared to analyst estimates of $339.97 million. During the same period last year, the firm earned $3.63 EPS. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. Equities analysts predict that United Therapeutics will post 9.52 EPS for the current year.
In other United Therapeutics news, CEO Martine A. Rothblatt sold 20,000 shares of the stock in a transaction that occurred on Friday, June 19th. The stock was sold at an average price of $116.35, for a total value of $2,327,000.00. Following the transaction, the chief executive officer now owns 10,140 shares in the company, valued at $1,179,789. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Raymond Dwek sold 4,600 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $116.81, for a total value of $537,326.00. Following the completion of the sale, the director now directly owns 4,600 shares of the company’s stock, valued at approximately $537,326. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 114,600 shares of company stock valued at $13,624,626. Insiders own 10.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. CWM LLC lifted its stake in shares of United Therapeutics by 696.2% in the second quarter. CWM LLC now owns 207 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 181 shares in the last quarter. Altshuler Shaham Ltd bought a new position in United Therapeutics in the 1st quarter valued at about $28,000. Signaturefd LLC increased its holdings in United Therapeutics by 139.6% during the 2nd quarter. Signaturefd LLC now owns 321 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 187 shares in the last quarter. CSat Investment Advisory L.P. raised its stake in shares of United Therapeutics by 198.3% in the second quarter. CSat Investment Advisory L.P. now owns 352 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 234 shares during the last quarter. Finally, FinTrust Capital Advisors LLC bought a new position in shares of United Therapeutics in the second quarter valued at approximately $51,000. 94.37% of the stock is owned by institutional investors and hedge funds.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
See Also: Straddles
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.